Zeng, Jin <br/><br/>
PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.  [electronic resource] 

 -  Theranostics  2018 
 - 109-123 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1838-7640 
<br/><br/><label>Standard No.: </label>10.7150/thno.20356  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AMP-Activated Protein Kinase Kinases<br/>AMP-Activated Protein Kinases--genetics<br/>Animals<br/>Apoptosis--drug effects<br/>Autophagy--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Docetaxel<br/>Flow Cytometry<br/>Humans<br/>Immunohistochemistry<br/>Immunoprecipitation<br/>Male<br/>Mice<br/>Mice, Nude<br/>Neoplasm Proteins--genetics<br/>Prostatic Neoplasms--drug therapy<br/>Protein Serine-Threonine Kinases--genetics<br/>Real-Time Polymerase Chain Reaction<br/>Signal Transduction--drug effects<br/>Taxoids--therapeutic use